Crescent Biopharma (CBIO) Stock Price, News & Analysis
What Changed
- Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
- BlackRock reports a stake above 5% in Crescent Biopharma (CBIO), with no shared voting power.
Price Move History
- Daily moves over 5%
- 63 252 sessions, October 28, 2025 to October 28, 2026
- Largest daily move
- +20.8% close of February 19, 2026
- 1-year change
- +8% closing prices, October 28, 2025 to October 28, 2026
- 1-month change
- -7.1% closing prices, September 28, 2026 to October 28, 2026
Company Description
Crescent Biopharma, Inc. (Nasdaq: CBIO) is a clinical-stage biotechnology company developing oncology therapeutics for solid tumors. The company’s pipeline is built around antibody-based drug candidates, led by CR-001, a PD-1 x VEGF bispecific antibody, and includes antibody-drug conjugate programs such as CR-002 and CR-003.
Crescent focuses on multiple therapeutic modalities and established oncology targets. Its development strategy includes evaluating drug candidates as single agents and as part of combination regimens for a range of solid tumor settings. The company has described CR-001 as its lead program and as a potential immuno-oncology backbone candidate, while its ADC programs extend the pipeline into targeted drug-delivery approaches.
Pipeline and development focus
The company’s lead clinical program, CR-001, is a bispecific antibody designed to engage both PD-1 and VEGF pathways. Crescent has described the ASCEND study as a Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types. The company’s pipeline also includes ADC programs directed at validated oncology targets, including CR-002, identified as a PD-L1-targeted ADC, and CR-003, identified as an ITGB6-targeted ADC.
Crescent has reported a partnership with Kelun-Biotech that expands its pipeline and supports combination development involving CR-001 and antibody-drug conjugates. The company’s oncology work is centered on solid tumors and on therapeutic approaches that combine immuno-oncology and targeted cytotoxic payload delivery.
Corporate profile
Crescent Biopharma’s ordinary shares trade on Nasdaq under the symbol CBIO. The company is incorporated in the Cayman Islands and maintains principal offices in Waltham, Massachusetts. As a clinical-stage biotechnology issuer, Crescent’s public-company disclosures primarily center on research and development activity, clinical programs, financing, equity compensation, governance, and capital structure rather than commercial product revenue.
Stock Performance
Crescent Biopharma (CBIO) closed at $13.50 on October 28, 2026. Over the past 12 months, the price has gained 8.0%.
CBIO Metrics & Rankings
Price returns through October 28, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Crescent Biopharma has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include clinical trial, earnings, offering. View all CBIO news →
SEC Filings
Crescent Biopharma has filed 10 recent SEC filings, including 7 Form 4, 1 Form 144, 1 Form SCHEDULE 13G, 1 Form 8-K. The most recent filing was submitted on October 27, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CBIO SEC filings →
Insider Radar
Insider selling at Crescent Biopharma over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Crescent Biopharma generated $10.8M in revenue in FY2025, operating income reached -$152.6M, and net income was -$153.9M. The company generated -$71.5M in operating cash flow. The current ratio was 6.56, measuring current assets divided by current liabilities.
Upcoming Events
CR-001 monotherapy results
CR-003 China data
Initial proof-of-concept data
CR-001 PoC data
CR-003 PoC data
ASCEND proof-of-concept data
Clinical readouts begin
First vesting (1/4)
25% option vesting
Option vesting period
Crescent Biopharma has 28 upcoming scheduled events. The next event, "CR-001 monotherapy results", is scheduled for January 1, 2027 (in 64 days). 13 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the CBIO stock price.
Short Interest History
Short interest in Crescent Biopharma (CBIO) currently stands at 4.8 million shares, up 40.2% from the previous reporting period, representing 13.0% of the float. Since October 2025, short interest has increased by 727.1%.
Days to Cover History
Days to cover for Crescent Biopharma (CBIO) currently stands at 6.8 days, down 19.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since October 2025, the figure has increased by 22.3%. Across the settlements charted above, it has ranged from 2.5 to 19.9 days.
CBIO Company Profile & Sector Positioning
Crescent Biopharma (CBIO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing CBIO often look at related companies in the same sector, including NeOnc Technologies Holdings, Inc. (NTHI), Kyverna Therapeutics, Inc. (KYTX), Nuvectis Pharma, Inc. (NVCT), Innate Pharma S.A. (IPHA), and Caribou Biosciences, Inc. (CRBU). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CBIO's relative position within its industry.